SCHEDULE 13G/A: BlackRock Discloses 6.9% Passive Stake in Rhythm Pharmaceuticals
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% passive beneficial ownership stake in Rhythm Pharmaceuticals Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 3 to Schedule 13G regarding its ownership in RHYTHM PHARMACEUTICALS INC.
- As of March 31, 2025, BlackRock, Inc. beneficially owns 4,364,700 shares of Common Stock of Rhythm Pharmaceuticals Inc.
- This represents 6.9% of the class of securities.
- BlackRock holds sole voting power over 4,304,827 shares and sole dispositive power over 4,364,700 shares.
- No shared voting or dispositive power is reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Various BlackRock business units, including BlackRock Advisors, LLC, BlackRock Investment Management (UK) Limited, and others, are involved, with at least one entity beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing disclosing passive ownership. It does not contain positive or negative news about the issuer's operations or financial performance.
Industry Context
This filing is a standard disclosure of institutional ownership by a major asset manager, BlackRock, in a biotechnology company, Rhythm Pharmaceuticals. It reflects BlackRock's ongoing investment activities and does not provide specific insights into broader industry trends or competitive landscape beyond indicating continued institutional interest in the pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can influence market perception of stability and institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revocation. |
| 2025-01-21 | Effective date of the new Power of Attorney. |
| 2025-03-31 | Date of event which requires filing of this statement. |
| 2025-04-24 | Date of filing/signature of the Schedule 13G Amendment No. 3. |
Keywords
Rhythm Pharmaceuticals, BlackRock, Schedule 13G, Passive Investment, Institutional Ownership, Common Stock, Biotechnology, Pharmaceuticals, SEC Filing, Ownership Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.